KATHERINE BUKOLT: Open Payments
NPI 1538324272 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,300 in 25 payments from 12 companies in 2025. Trend: 2023 $1,781 · 2024 $1,064 · 2025 $1,300
Food & beverage: $1,300
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $230 |
| ABBVIE INC. | 5 | $194 |
| AstraZeneca Pharmaceuticals LP | 4 | $191 |
| BeOne Medicines USA, Inc. | 1 | $143 |
| Pharmacosmos Therapeutics Inc. | 1 | $134 |
| Adaptive Biotechnologies Corporation | 1 | $123 |
| Novartis Pharmaceuticals Corporation | 2 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $54 |
| Merck Sharp & Dohme LLC | 2 | $52 |
Products named: FRUZAQLA, BRUKINSA, MONOFERRIC, clonoSEQ, PLUVICTO, IMFINZI, Enhertu, EPKINLY.
Industry payments across TX — which companies pay providers there.
